Lexeo Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Lexeo Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Lexeo Therapeutics: 6 sponsored US clinical trials, 2 recruiting.
Lexeo Therapeutics sponsors 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is PKP2-ARVC, with 2 trials.
Upper-quartile sponsor footprint
Lexeo Therapeutics sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
Clinical Course Of Disease In Participants With FA-CM
NCT06865482
A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM
NCT06976606
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
NCT06109181
Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease
NCT05400330
Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia
NCT05445323
Gene Therapy for APOE4 Homozygote of Alzheimer's Disease
NCT03634007
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
Therapeutic Areas
What is open in the Lexeo Therapeutics pipeline
2 recruiting of 6 indexed (33% open); 1 completed (17%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: PKP2-ARVC (2 trials), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Lexeo Therapeutics: open-pipeline peers nationwide
Peers matched on 6 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Lexeo Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Lexeo Therapeutics page
6 registered trials is a research-attention snapshot, not an endorsement of Lexeo Therapeutics or any single study.
- 2 of Lexeo Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- PKP2-ARVC is the condition Lexeo Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See PKP2-ARVC trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Lexeo Therapeutics pipeline card: 6 registered trials from official public datasets.Report a data error.